Related references
Note: Only part of the references are listed.Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study
Katja Kollewe et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Wearing Off Effect of OnabotulinumtoxinA Near the End of Treatment Cycle for Chronic Migraine: A 4-Year Clinical Experience
Fawad A. Khan et al.
HEADACHE (2020)
Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice
Olivia Begasse de Dhaem et al.
HEADACHE (2020)
Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data
Raffaele Ornello et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway
Amanda Hansson-Hedblom et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA
Marta Torres-Ferrus et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States
Machaon Bonafede et al.
HEADACHE (2018)
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Spencer L. G. James et al.
LANCET (2018)
Botulinum toxin in the management of chronic migraine: clinical evidence and experience
Claus M. Escher et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2017)
Efficacy of different doses of botox in treatment of chronic migraine
M. V. Naprienko et al.
Zhurnal Nevrologii I Psikhiatrii imeni S S Korsakova (2017)
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program
Richard B. Lipton et al.
CEPHALALGIA (2016)
Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey
Andrew Messali et al.
HEADACHE (2016)
Impact of depression and anxiety on burden and management of episodic and chronic headaches - a cross-sectional multicentre study in eight Austrian headache centres
Karin Zebenholzer et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects
Dirk Dressler et al.
JOURNAL OF NEURAL TRANSMISSION (2015)
Therapeutic use of botulinum toxin in migraine: mechanisms of action
Roshni Ramachandran et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
An Exploratory Study of Salivary Calcitonin Gene-Related Peptide Levels Relative to Acute Interventions and Preventative Treatment With OnabotulinumtoxinA in Chronic Migraine
Roger Cady et al.
HEADACHE (2014)
Economic Burden and Costs of Chronic Migraine
Michel Lanteri-Minet
CURRENT PAIN AND HEADACHE REPORTS (2013)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program
Sheena K. Aurora et al.
HEADACHE (2011)
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine
R. B. Lipton et al.
NEUROLOGY (2011)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
S. K. Aurora et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. C. Diener et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
David W. Dodick et al.
HEADACHE (2010)
The Epidemiology of Primary Headache Disorders
Matthew S. Robbins et al.
SEMINARS IN NEUROLOGY (2010)
Neutralizing Antibodies and Secondary Therapy Failure After Treatment With Botulinum Toxin Type A: Much Ado About Nothing?
Oliver Lange et al.
CLINICAL NEUROPHARMACOLOGY (2009)
Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain
Daniele Ranoux et al.
ANNALS OF NEUROLOGY (2008)
Migraine prevalence, disease burden, and the need for preventive therapy
R. B. Lipton et al.
NEUROLOGY (2007)
Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport®) for the relief of upper back myofascial pain syndrome:: Results from a randomized double-blind placebo-controlled multicentre study
Hartmut Goebel et al.
PAIN (2006)
Botulinum toxin type A for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial
SD Silberstein et al.
MAYO CLINIC PROCEEDINGS (2005)
Medication-overuse headache: a worldwide problem
HC Diener et al.
LANCET NEUROLOGY (2004)
The economic impact of migraine: An analysis of direct and indirect costs
J Edmeads et al.
HEADACHE (2002)
Share Paper
